These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 29173689)
41. Health-related quality of life in children and adolescents with juvenile localized scleroderma. Orzechowski NM; Davis DM; Mason TG; Crowson CS; Reed AM Rheumatology (Oxford); 2009 Jun; 48(6):670-2. PubMed ID: 19336577 [TBL] [Abstract][Full Text] [Related]
42. Thrombocytopenia Associated with Localized Scleroderma: Report of Four Pediatric Cases and Review of the Literature. Jindal AK; Gupta A; Dogra S; Rawat A; Suri D; Ahluwalia J; Singh S Pediatr Dermatol; 2017 Jul; 34(4):e174-e178. PubMed ID: 28543515 [TBL] [Abstract][Full Text] [Related]
43. Cardiovascular assessment of asymptomatic patients with juvenile-onset localized and systemic scleroderma: 10 years prospective observation. Borowiec A; Dabrowski R; Wozniak J; Jasek S; Chwyczko T; Kowalik I; Musiej-Nowakowska E; Szwed H Scand J Rheumatol; 2012 Feb; 41(1):33-8. PubMed ID: 22103465 [TBL] [Abstract][Full Text] [Related]
44. Initial Results from a Pilot Comparative Effectiveness Study of 3 Methotrexate-based Consensus Treatment Plans for Juvenile Localized Scleroderma. Li SC; Torok KS; Rabinovich CE; Dedeoglu F; Becker ML; Ferguson PJ; Hong SD; Ibarra MF; Stewart K; Pope E; Higgins GC; Laxer RM; Mason T; Fuhlbrigge RC; Andrews T; J Rheumatol; 2020 Aug; 47(8):1242-1252. PubMed ID: 31615917 [TBL] [Abstract][Full Text] [Related]
45. Baseline Description of the Juvenile Localized Scleroderma Subgroup From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry. Wu EY; Li SC; Torok KS; Virkud YV; Fuhlbrigge RC; Rabinovich CE; ACR Open Rheumatol; 2019 Apr; 1(2):119-124. PubMed ID: 31777788 [TBL] [Abstract][Full Text] [Related]
46. Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Zulian F; Martini G; Vallongo C; Vittadello F; Falcini F; Patrizi A; Alessio M; La Torre F; Podda RA; Gerloni V; Cutrone M; Belloni-Fortina A; Paradisi M; Martino S; Perilongo G Arthritis Rheum; 2011 Jul; 63(7):1998-2006. PubMed ID: 21305525 [TBL] [Abstract][Full Text] [Related]
47. Pediatric morphea (localized scleroderma): review of 136 patients. Christen-Zaech S; Hakim MD; Afsar FS; Paller AS J Am Acad Dermatol; 2008 Sep; 59(3):385-96. PubMed ID: 18571769 [TBL] [Abstract][Full Text] [Related]
48. Consensus-based recommendations for the management of juvenile localised scleroderma. Zulian F; Culpo R; Sperotto F; Anton J; Avcin T; Baildam EM; Boros C; Chaitow J; Constantin T; Kasapcopur O; Knupp Feitosa de Oliveira S; Pilkington CA; Russo R; Toplak N; van Royen A; Saad Magalhães C; Vastert SJ; Wulffraat NM; Foeldvari I Ann Rheum Dis; 2019 Aug; 78(8):1019-1024. PubMed ID: 30826775 [TBL] [Abstract][Full Text] [Related]
49. Scleroderma in children. Zulian F Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):576-595. PubMed ID: 29773274 [TBL] [Abstract][Full Text] [Related]
50. Reliability of LoSCAT score for activity and tissue damage assessment in a large cohort of patients with Juvenile Localized Scleroderma. Agazzi A; Fadanelli G; Vittadello F; Zulian F; Martini G Pediatr Rheumatol Online J; 2018 Jun; 16(1):37. PubMed ID: 29914516 [TBL] [Abstract][Full Text] [Related]
51. United Kingdom survey of current management of juvenile localized scleroderma. Hawley DP; Pain CE; Baildam EM; Murphy R; Taylor AE; Foster HE Rheumatology (Oxford); 2014 Oct; 53(10):1849-54. PubMed ID: 24850875 [TBL] [Abstract][Full Text] [Related]
52. Body site distribution of pediatric-onset morphea and association with extracutaneous manifestations. Chiu YE; Shmuylovich L; Kiguradze T; Anderson K; Sibbald C; Tollefson M; Kunzler E; Tom WL; Bond K; Ahmad RC; Garcia-Romero MT; Irfan M; Kollman K; Hunt R; Stein SL; Arkin L; Wong V; Pope E; Jacobe H; Brandling-Bennett HA; Cordoro KM; Bercovitch L; Rangel SM; Liu X; Szabo A; Paller AS J Am Acad Dermatol; 2021 Jul; 85(1):38-45. PubMed ID: 33689776 [TBL] [Abstract][Full Text] [Related]
53. [Clinical characteristics of patients with juvenile localized scleroderma]. Sun QN; Du W; Hu B; Liu P; Yuan X Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Feb; 31(1):48-50. PubMed ID: 19317059 [TBL] [Abstract][Full Text] [Related]
54. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Leitenberger JJ; Cayce RL; Haley RW; Adams-Huet B; Bergstresser PR; Jacobe HT Arch Dermatol; 2009 May; 145(5):545-50. PubMed ID: 19451498 [TBL] [Abstract][Full Text] [Related]
55. [Localized scleroderma (morphea) in childhood]. Weibel L Hautarzt; 2012 Feb; 63(2):89-96. PubMed ID: 22290277 [TBL] [Abstract][Full Text] [Related]
56. Orthopedic complications of linear morphea: Implications for early interdisciplinary care. Schoch JJ; Schoch BS; Werthel JD; McIntosh AL; Davis DMR Pediatr Dermatol; 2018 Jan; 35(1):43-46. PubMed ID: 29119592 [TBL] [Abstract][Full Text] [Related]